Double RESI Conference Panel Announcement: Big Pharma & Diagnostic Investors

4 Dec

By Tom Crosby, RESI Conference Manager, LSN

Tom 2This week, LSN announces two panels for the upcoming Redefining Early Stage Investments Conference: Big Pharma & Large Biotech, and Diagnostic Investors.

Panel Announcement #1: Big Pharma

Panelists will discuss in-depth the key motivators behind big pharma’s shift towards an early stage strategy as a way to fill the gaps in their pipelines. What indication areas are currently most sought after? How does an early stage entrepreneur interface with business development executives from pharmaceutical companies? LSN’s Big Pharma RESI Panelists will shed light on these questions and more.

Moderated by Tomas Landh, Director, Novo Nordisk, the audience will hear from:

Kevin Lynch, VP, Search and Evaluation, Abbvie

Imran Nasrullah, Director, Innovation Sourcing, Boehringer Ingelheim

Thorsten Melcher, Senior Director, New Ventures & Partnerships, J&J Innovation

Shafique Virani, Global Head, Partnering (Neuro), Roche / Genentech

Hear from big pharma executives as they explain how they engage with early stage startups, and how they like to be contacted. The speakers will help the audience understand their timeline for contact, and give advice on how to create a dialogue that leads to a relationship and an eventual alliance. If you need to understand the timeframe and limitations of how big pharma corporate works, this expert session is crucial for you to attend.

Panel Announcement #2: Diagnostic Investors

In addition to drug developers and medical device engineers, LSN also welcomes diagnostic startups to RESI, and for the first time, RESI 4 will present a discussion panel exploring the challenging landscape of the diagnostics sector. The investors joining this panel are highly diverse, representing both nonprofit and for-profit interests in the diagnostics field.

These panelists will discuss what an entrepreneur needs to know about raising capital for an innovative diagnostic product. The panel will explore how to pitch a diagnostic opportunity, how to navigate the strategic challenges in diagnostics, and what will differentiate your product from the pack.

Moderated by Steven Young, President & COO, Addario Lung Cancer Institute, the audience will hear from:

Bill Cadwallader, Senior Commercialization Officer, Diagnostics, PATH

Momei Qu, Senior Associate, Baird Capital

Gary Kurtzman, Senior Vice President and Managing Director, HealthcareSafeguard Scientifics, Inc.

Nola Masterson, Founder and Managing Director, Science Futures

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: